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Abstract
Approximately half of all patients with chronic obstructive pulmonary disease (COPD) attending pulmonary
rehabilitation (PR) programmes are overweight or obese which negatively impacts upon dyspnoea and exercise
tolerance particularly when walking. Within the obese population (without COPD), the observed
heterogeneity in prognosis is in part explained by the variability in the risk of developing cardiovascular
disease or diabetes (cardiometabolic risk) leading to the description of metabolic syndrome. In obesity
alone, high-intensity aerobic training can support healthy weight loss and improve the constituent
components of metabolic syndrome. Those with COPD, obesity and/or metabolic syndrome undergoing PR
appear to do as well in traditional outcomes as their normal-weight metabolically healthy peers in terms of
improvement of symptoms, health-related quality of life and exercise performance, and should therefore not
be excluded. To broaden the benefit of PR, for this complex population, we should learn from the extensive
literature examining the effects of exercise in obesity and metabolic syndrome discussed in this review and
optimize the exercise strategy to improve these co-morbid conditions. Standard PR outcomes could be
expanded to include cardiometabolic risk reduction to lower future morbidity and mortality; to this end
exercise may well be the answer.
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Prevalence of obesity in COPD
The effect of body composition upon clinical
outcomes in individuals with chronic obstructive pul-
monary disease (COPD) has been a focus for
researchers and clinicians for decades. However, the
lower end of the body mass index (BMI) spectrum and
cachexia have predominated and justified by the asso-
ciated poor prognosis1 of this habitus. Towards the
21st century, the obesity epidemic encompassed
patients with COPD where the prevalence of obesity
(BMI > 30 m kg2)2 is reported to be between 10%
and 30% depending on the country of origin and
severity of disease.3–5 The majority of patients with
COPD in typical pulmonary rehabilitation (PR)
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populations6 and in large randomized controlled trials
of pharmacological therapy are overweight.7 Con-
flicting results remain regarding the prevalence of
obesity between those with and without COPD from
epidemiological studies with similar, higher and
lower prevalence all reported for those with
COPD.3,8,9
Obesity and mortality
In non-COPD populations, the relationship between
BMI and mortality has been described by a ‘J-shaped
curve’, but the magnitude of the increased risk of
death per increase in BMI is unknown. Furthermore,
reduced functional status, frequency and type of co-
morbid conditions have a greater association with
mortality than a high BMI alone.10,11 Physical inac-
tivity is implicated as a factor in the development of
obesity inferring a negative impact upon clinical out-
comes. In addition, individuals with obesity, who are
fit, do better than their lean unfit counterparts.12 Stud-
ies exploring the obesity ‘paradox’ have subcategor-
ized individuals with obesity into metabolically healthy
or unhealthy13 with an increase in coronary artery dis-
ease reported in those who are metabolically
‘unhealthy’ (or have the metabolic syndrome).14 The
concept of ‘metabolically healthy’ obesity is still being
debated as this group appears to sustainmore cardiovas-
cular events compared with the people of normal
weight.13
BMI and prognosis in individuals with COPD
In populations with COPD, a paradox is described
whereby patients with a higher BMI live longer than
those with either a low or normal index particularly in
those with severe disease.15 The severity of COPD is
predominantly assessed by the degree of airflow
impairment so one explanation may be that the sever-
ity of COPD is overestimated by the physiological
reduction in lung volumes in obese individuals.
Furthermore, when carbon dioxide levels, muscle
mass (measured by thigh cross-sectional area) and
exercise capacity are included, the obesity paradox
appears to disappear.16 Physical inactivity and
co-morbid conditions both negatively impact survival
in individuals with COPD,17,18 similar to the obese
individuals without COPD. An increased risk of heart
failure, diabetes and hypertension is seen in COPD
associated with increased systemic inflammation18;
metabolic disturbances may be implicated as part of
the pathophysiological mechanisms.
Metabolic syndrome and COPD
Metabolic syndrome: an evolving definition
The co-existence of several metabolic disturbances,
namely obesity, dyslipidaemia, hypertension and
hyperglycaemia, has been increasingly observed
over the last century and led to the description of
a ‘metabolic syndrome’.19 Originally defined by
Reaven as ‘Syndrome X’ through identifying the
relationship between insulin resistance, hyperinsu-
linemia, hypertension, coronary artery disease and
noninsulin-dependent diabetes mellitus.20 In 1998,
the World Health Organization was the first to for-
malize the definition of a metabolic syndrome cre-
ating a working definition3: ‘the occurrence of
“glucose intolerance, impaired glucose tolerance
or diabetes mellitus and/or insulin resistance
together with two or more of the components
below”:
1. Raised arterial pressure > 160/90 mmHg
2. Raised plasma triglycerides (>1.7 mmol L1;
150 mg dL1) and/or low high-density
lipoprotein-cholesterol (<0.9 mmol L1; 35
mg dL1 men; <1.0 mmol L1; 39 mg dL1
women)
3. Central obesity (males: waist to hip ratio >
0.90; females: waist to hip ratio > 0.85) and/
or BMI > 30 kg m2
4. Microalbuminuria (urinary albumin excretion
rate > 20 mg min1 or albumin: creatinine ratio
> 20 mg g1)’
The term metabolic syndrome or ‘cardiometabolic
syndrome’ is commonly used today to describe the
interaction between cardiovascular, renal, meta-
bolic, prothrombotic and inflammatory abnormal-
ities leading to increased morbidity and
mortality.21 The development of metabolic syn-
drome is thought to be closely associated with phys-
ical inactivity leading to the accumulation of visceral
fat, which activates pro-inflammatory pathways
leading to type II diabetes mellitus and cardiovascu-
lar disease.12
Whilst the common features of metabolic syn-
drome are generally accepted, the precise definition
is continuing to be refined; probably the most univer-
sally accepted is the 2009 joint consensus
definition,22 which is slightly modified from that pro-
posed by the International Diabetes Federation in
200623 (Table 1).
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Prevalence of metabolic syndrome in COPD
Data from the 2003 to 2012 National Health and Nutri-
tion Examination Survey collected in the United States
concluded the prevalence of metabolic syndrome was
33%, with a significantly higher prevalence in women
than men (35.6% vs. 30.3%, respectively).24 The pre-
valence of metabolic syndrome among those with
COPD is reported to be anywhere between 21% and
58% depending on disease severity, geographic loca-
tion, definition utilized and the assessments made.25
There is a suggestion that metabolic syndrome is more
prevalent in those with milder airflow obstruction,25,26
but this may in part reflect the weight loss observed in
the severe stages of COPD. Single studies have
reported a higher prevalence of metabolic syndrome
than age- and gender-matched individuals without
COPD.27 However, pooled estimates of 10 studies
reported similar (32% vs. 30%) prevalence of meta-
bolic syndrome between COPD and healthy controls.25
In contrast, a prospective study, where the components
of the metabolic syndrome were objectively assessed,
reported a prevalence of 57% in 228 participants,
which was significantly higher than healthy controls
(40%).28 The results from this study suggested that the
presence of metabolic syndrome did not impact the
functional outcomes in those with COPD.
Cardiovascular disease and diabetes are significant
causes of morbidity and mortality for patients with
COPD, and their prevalence is significantly
higher than in matched-controls. This association
likely relates to several pathophysiological mechan-
isms, including systemic inflammation, physical inac-
tivity and oxidative stress.26,29 International COPD
guidelines recommend ‘the proactive identification
and treatment of comorbidities’,30 yet often this is
routinely performed in clinical practice. Whether ear-
lier identification and management of metabolic syn-
drome in patients with COPD would lower the risk of
developing cardiovascular disease and improve long-
term clinical outcomes is unclear.
There is also intriguing evidence that diabetes mel-
litus and metabolic syndrome through an inflammatory
mechanism result in airflow obstruction31,32 rather
than metabolic derangement occurring in COPD as a
co-morbidity. Whether effective metabolic manage-
ment may slow the progression of airflow limitation
in patients with COPD is yet unknown.
Obesity and metabolic syndrome are common in
patients with COPD who are symptomatic and
referred for PR.6,27 Despite the association between
obesity in COPD and a reduced exercise performance
compared to normal-weight individuals, obese indi-
viduals gain similar improvements with PR in terms
of exercise capacity and health-related quality of life
as patients who are normal weight.6 However, weight
loss is not often a specific goal of PR and not achieved
by most standard PR programmes.
If co-morbidities such as obesity and metabolic
syndrome are to be addressed in the personalization
of PR delivery, it is important to understand the cur-
rent recommendations for exercise therapy for both of
these conditions when COPD is not present.
Obesity and exercise interventions
Obesity is considered the result of a complex interplay
of individual and environmental factors; therefore, its
Table 1. Definition of metabolic syndrome.
2009 Consensus definition criteria for the clinical diagnosis of the metabolic syndrome: present if any three of the criteria
are might shown below:
2006 IDF definition criteria for the diagnosis of the metabolic syndrome present if central obesity (defined as waist
circumference with ethnicity specific values, or assumed if BMI is greater than 30 kg m2) is present plus any two of the
following four factors:
Measure Categorical cut points
Elevated waist circumferencea Population and country-specific definitions
Elevated triglycerides (or drug treatment for this disturbance) 150 mg dL1 (1.7 mmol L1)
Reduced HDL (or drug treatment for this disturbance) <40 mg dL1 (1.0 mmol L1) in males; <50 mg dL1
(1.3 mmol L1) in females
Elevated blood pressure (or drug treatment for this disturbance or
previous hypertension diagnosis)
Systolic  130 and/or diastolic  85 mm Hg
Elevated fasting glucose (or drug treatment for this disturbance) 100 mg dL1
IDF: International Diabetes Federation; BMI: body mass index; HDL: high-density lipoprotein.
aHas to be present for the 2009 definition.
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management demands a comprehensive approach.33
Exercise is an important component of this approach,
the goals of which include improvements in general
health and reduction in risk of comorbid disease in
addition to weight loss.33,34
Weight loss requires a shift in energy balance of
which exercise forms a negative component of the
equation.35 As such sufficient quantities of exercise
must be achieved without compensatory behaviours
such as increased calorie intake. The absolute quantity
of exercise or activity appears to be more important
than the type or intensity; individuals exercising at
lower intensity can achieve similar weight changes
by increasing duration, and greater improvements in
weight reduction are seen with increasing overall
amount.36,37 Results from the studies of a targeted risk
reduction intervention through defined exercise
(STRRIDE) study, a randomized control study inves-
tigating the effects of exercise duration and intensity
in overweight and obese adults, suggest that an equiv-
alent volume above 6–7 miles a week may be required
in order to achieve weight loss. Going further, a 14-
week daily exercise program where obese women
were asked to expend approximately 500 kcal resulted
in an average body weight reduction of 6.5%.38 A
similar study in obese men where daily expenditure
was approximately 700 kcal resulted in an 8% reduc-
tion over 3 months. Studies have tended to focus on
aerobic exercise interventions for weight loss employ-
ing a range of modalities, including walking, station-
ary cycling and elliptical cross trainers, and the
evidence seems to support this approach.36–38 There
may be additional gains and other benefits, for exam-
ple, on body composition, muscle strength and cardi-
ovascular fitness, through the addition of high
intensity or resistance exercise.36,39,40
Weight loss alone has the potential to impact sev-
eral of the adverse health risk factors, which are
highly prevalent in obesity, such as hypertension, dys-
lipidaemia and insulin resistance.41–46 However, exer-
cise may deliver improvements in these elements
above that achieved through weight reduction and
even when weight remains stable.35,38,47
Where studies have specifically examined the
effects of exercise in overweight and obese individu-
als, improvements in blood pressure, lipid profiles,
glucose, glycosylated haemoglobin (HbA1c) and
insulin sensitivity46–49 have been described. Again the
overall volume of exercise appears to be more impor-
tant than exercise modality for most of these risk
factors, and modification has been demonstrated with
even small increases in weekly exercise although
larger volumes of moderate exercise appear to result
in greater effects on lipid and glycaemic profiles.48,50–54
In those with established type II diabetes, a meta-
analysis demonstrated improvements in levels of
HbA1c through either aerobic, resistance or combined
exercise, and such improvements have also been seen
in obese groups.55,56
In addition to the effects on risk factor modifica-
tion, exercise can enhance cardiovascular fitness,
which is also related to a lower all-cause and cardio-
vascular mortality, and improve social engagement
and measures of well-being.57–59
How these elements are combined to form the opti-
mal exercise prescription to achieve both increased
energy expenditure to aid healthy weight loss and
evoke an important cardiovascular stimulus is still
unknown. Clinicians and researchers often quote that
weight supported exercise should be the initial mod-
ality. In a direct comparison of weight supported and
unsupported (cycling versus treadmill walking) exer-
cise at 60% and 80% VO2 peak, treadmill walking
was associated with the greatest energy expenditure
and with a higher cardiovascular stimulus in obese
individuals.60 However, whether this translates to a
more effective training regime with the additional
factors of comfort, tolerance and compliance remains
unknown.
Uncertainty exists around the translation of
research to the prescription for an individual. Individ-
ual barriers, such as time, physical discomfort, and
embarrassment as well as physical mobility and
equipment weight limitations, are important to
address.61 Adherence can be an issue, with many
trials demonstrating a significant drop-out rate in the
exercise intervention group.33,36,37 Therefore, indi-
vidual tailoring, focusing on meaningful and realistic
goals with adequate support, is a proposed
strategy.33,34,36
The effects of obesity on exercise in individuals
with COPD
Obesity can impair exercise capacity due to the
increased mechanical load from carrying the extra
weight, altered economy due to gait alterations and
joint and spine discomfort. In COPD, the addition of
obesity further impairs walking performance indepen-
dent of the degree of airflow limitation. An interesting
phenomenon has been demonstrated, whereby, in
individuals with COPD and obesity, the development
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of dynamic hyperinflation during cycling is lower in
obese individuals compared to normal weight.62
Furthermore, the relationship between the progression
of breathlessness with increasing ventilation is similar
between walking and cycling in obese individuals
with COPD,63 whereas in obese individuals without
COPD, there is a greater progression of breathlessness
with cycling compared to treadmill walking and ear-
lier termination of exercise.60
The effects of exercise training upon the
metabolic syndrome
A large randomized controlled trial confirmed the
evidence from smaller trials demonstrating that a
period of aerobic exercise training in otherwise
healthy adults with metabolic syndrome achieves a
reduction in some but not all of the constituent com-
ponents. Markers of insulin resistance and systemic
inflammation have also been seen to be reduced after
three months of high-intensity exercise training in
adults with type II diabetes mellitus and the metabolic
syndrome64 appearing to be related to gains in peak
oxygen uptake (cardiorespiratory fitness) rather than
weight loss. Similarly, a small study reported that
high-intensity aerobic training (via an interval train-
ing regime) improved the constituent components of
metabolic syndrome greater than moderate intensity
training (via a continuous training regime).65 Other
modalities of exercise training have also been tested
such as resistance training where the hypothesis is
based around increasing muscle mass to reduce insu-
lin resistance. However, the results to date have been
inconsistent: a meta-analysis showed resistance train-
ing significantly reduced the levels of HbA1c in
adults with abnormal glucose metabolism with a
reduction in body fat mass and visceral adipose
tissue.66 The results of a large randomized trial were
published a year later,67 concluding resistance train-
ing alone did not improve any parameters of the meta-
bolic syndrome, whereas aerobic training alone
showed a reduction in metabolic syndrome although
not significantly greater than combined aerobic and
resistance training. The training period was over 8
months and included adults who were overweight
with dyslipidaemia. Other research has concentrated
on how the effects of exercise upon metabolic syn-
drome may be attenuated by age, race and gender.
Overall, it appears that there is a beneficial effect
of high-intensity aerobic exercise training upon the
components of metabolic syndrome in adults who are
overweight or obese. Correspondingly, physically
active individuals have lower rates of all-cause
mortality, cardiovascular disease, hypertension and
importantly the metabolic syndrome.68 There is a con-
vincing body of literature to support this and interna-
tional guidelines promoting physical activity in all
adults.68 Physical activity is a complex construct
involving intense (aerobic exercise), mild and moder-
ate physical activities, and time being very inactive
(sedentary). Although there is interest in promoting
adults (particularly those with long-term conditions)
to be less sedentary, prospective data showing a
reduction in long-term risk compared with increasing
moderate or intense physical activity are not yet
available.69
Exercise training, COPD and
metabolic syndrome
People with co-existing COPD and metabolic syn-
drome appear to benefit comparably from a course
of PR as patients with COPD alone70 in terms of
health-related quality of life and exercise perfor-
mance. Similarly, studies have investigated the effects
of co-morbidities on the outcomes of PR,71 but to
date, there has been far less focus on the effects of
PR on the underlying co-morbid conditions such as
metabolic syndrome. A couple of studies have inves-
tigated the effects of PR in patients with COPD on
cardiovascular risk by assessing systemic blood pres-
sure, lipid levels and aortic stiffness but found differ-
ing results.72,73
There are surprisingly few studies examining the
effects of standard rehabilitation on all the constituent
parts of the metabolic syndrome or on different mod-
alities. Although high-intensity aerobic training pro-
grammes have been found to improve metabolic
syndrome in those without COPD, whether the rela-
tive rather than absolute high-intensity training
achieved in people with COPD would be enough to
improve metabolic syndrome, or whether strategies to
increase the muscle-specific stimulus would be opti-
mal remains unanswered.
Currently, the evidence base and data for cost-
effectiveness of PR is derived from patients who have
significant dyspnoea rendering them unable to walk at
their own pace on the flat without stopping.74 The
aim, for this population, has been to reduce dyspnoea
and improve the quality of life, which PR does very
successfully.75 However, perhaps the focus should
also be to reduce cardiometabolic risk (the risk of
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developing cardiovascular disease and/or diabetes)
which may be even more relevant when designing
exercise or physical activity interventions for those
with milder disease. The duration of standard PR is
typically 6–12 weeks and it is also unknown if this is
sufficient to reduce cardiometabolic risk in the longer
term. Even if some benefits were observed in the short
term, it is likely that long-term behaviour change and
healthy lifestyle adaptations would be necessary to
impact upon long-term cardiometabolic risk.
In summary, co-morbid conditions of obesity and
metabolic syndrome are common in COPD. In those
without COPD, exercise and high-intensity physical
activity can support healthy weight loss and improve
the constituent components of the metabolic syn-
drome. Those with COPD, obesity and/or metabolic
syndrome undergoing PR appear to do as well as their
normal-weight metabolically healthy peers and
should therefore not be excluded. To progress the
benefit of PR for this complex population, we should
learn from the extensive literature examining the
effects of exercise in obesity and metabolic syndrome
and target the exercise strategy to ameliorate these co-
morbid conditions. Standard PR outcomes should be
expanded to include cardiometabolic risk reduction in
order to lower future morbidity and mortality; to this
end, exercise may well be the answer.
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